FISH diagnostics in plasma cell myeloma: recommendations and own experience

Plasma cell myeloma (PCM) is disease with heterogeneous clinical outcomes. It increasingly evident that the genetic features of tumor cells largely dictate heterogeneity PCM. Primary chromosomal alterations in can be divided into hyperdiploid and non-hyperdiploid subtypes. Secondary changes occur during progression disease. Cytogenetic abnormalities are important prognostic markers PCM some them were incorporated current staging system The presence t(4;14), t(14;16), t(14;20), gain 1q or TP53 deletion considered to high-risk myeloma. Detection these performed by interphase fluorescence situ hybridization (FISH) after separation identification plasma cells. proper FISH examination has meet further requirements regarding aspirating timing samples, probe selection their cut-off levels, criteria accurate analysis reporting. Based on literature, we here present technical recommendations Furthermore, share our own experience diagnostics acquired over 12 years. In this period, have nearly 2,050 tests 603 patients used two different methods FISH: immunolabeled cells, target BioView system.